Alnylam Announces Manufacturing Agreement with DowpharmaSM for RNAi Therapeutics
"This agreement is an important step in our transition to a clinical-stage company as we rapidly advance multiple RNAi therapeutic candidates into human trials," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "Dowpharma is a high-quality partner who will provide Alnylam access to large-scale synthesis and purification of siRNAs necessary for clinical development."
The Dowpharma contract service agreement will provide Alnylam with large quantities of GMP-certified siRNAs necessary for near-term toxicology and clinical studies on RNAi therapeutic candidates. Dowpharma will manufacture siRNAs for use in certain Alnylam programs, including those in AMD and RSV.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.